Clinical trials
Lymphangioleiomyomatosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 6 |
| Active, not recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 7 |
| University of Cincinnati | 5 |
| Brigham and Women's Hospital | 3 |
| Children's Hospital Medical Center, Cincinnati | 2 |
| Novartis Pharmaceuticals | 2 |
| Columbia University | 1 |
| David M. Ritter | 1 |
| M.D. Anderson Cancer Center | 1 |
| Medical University of South Carolina | 1 |
| National Tuberous Sclerosis Association | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphangioleiomyomatosis | 27 |
| Tuberous Sclerosis | 10 |
| Ascites | 2 |
| Hereditary Sensory and Autonomic Neuropathies | 2 |
| Lung Diseases | 2 |
| Lymphangiomyoma | 2 |
| Pneumothorax | 2 |
| Angiomyolipoma | 1 |
| Asthma | 1 |
| Astrocytoma | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.